RxDoctor Payments Data

Debra Durham, MD

Internal Medicine · Parks, LANPI 1386646677

Payments from drug & device makers

$608in general payments, 2019–2025

Across 36 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$94
  • Takeda Pharmaceuticals U.S.A., Inc.$94
  • Pfizer$62
  • AbbVie$57
  • Exact Sciences$54
  • Daiichi Sankyo Inc.$46
  • plus $200 from 10 others

What the payments were for

  • Food & beverage$608100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$608 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$121,652
Medicare patients
289
Services billed
1,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$136,589
JardianceEmpagliflozin176$117,496
XareltoRivaroxaban72$38,213
EliquisApixaban60$33,503
LinzessLinaclotide51$31,344
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$28,908
TrulicityDulaglutide27$26,841
Breo ElliptaFluticasone/Vilanterol49$22,679
FarxigaDapagliflozin Propanediol26$14,906
TrintellixVortioxetine Hydrobromide16$11,237
NamzaricMemantine Hcl/Donepezil Hcl28$11,221
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$9,617
Dexlansoprazole DrDexlansoprazole32$8,226
MyrbetriqMirabegron18$8,119
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$7,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$15$117,496176 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$12$61,204103 claims
AbbVieLinzess, Namzaric, Synthroid$57$44,219112 claims
Johnson & JohnsonXarelto$14$38,21372 claims
PfizerEliquis$62$33,50360 claims
Lilly USA, LLCTrulicity$94$26,84127 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$94$11,23716 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$37$7,28813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Parks

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →